ArticleBMC ophthalmology2025
Multicentric Castleman disease presenting with orbital involvement progressing to TAFRO syndrome: a case report.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCastleman Disease (CD) can be unicentric or multicentric, with the ocular involvement rare; notably, the aggressive TAFRO syndrome (TS) is a subtype of idiopathic multicentric CD (iMCD). Ocular involvement in CD is rare, and to date, there are no reported cases of progression from ocular involvement to TAFRO syndrome. CASE PRESENTATION: A 45-year-old woman with a six-year history of progressive, non-painful eyelid redness and protrusion presented with recent systemic symptoms including limb edema and fever. Laboratory tests indicated anemia, thrombocytopenia, and elevated levels of Interleukin (IL)-6 and vascular endothelial growth factor (VEGF), while imaging revealed bilateral orbital masses, multiple lymphadenopathies, splenomegaly, and pleural and abdominal effusions. Diagnosed with iMCD-TAFRO syndrome through comprehensive laboratory tests and multi-site biopsies. After intensive chemotherapy treatment, the patient achieved complete remission (CR) and is currently under regular follow-up.
conclusionHere, we present the first reported case of iMCD initially manifesting with ocular symptoms, subsequently progressing to TS, highlighting the need for heightened clinical awareness and multidisciplinary collaboration in the diagnosis and management of such atypical aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.